Observational studyBrain and behavior2021
Effects of safinamide on pain in patients with fluctuating Parkinson's disease.
Observational study in Brain and behavior, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Health-related quality of life in Parkinson's disease: systematic review and meta-analysis of EuroQol (EQ-5D) utility scores.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Pooled it
- Electrophysiological Evidence for Impaired Central Pain Modulation in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Pain in Parkinson's disease is impacted by motor complications, anxiety and sleep disturbances.European journal of pain (London, England) · 2025Observational
- Non-Motor Fluctuations in Parkinson's Disease: Underdiagnosed Yet Important.Journal of movement disorders · 2025Article
- Observational
- Optimized use of safinamide as an add-on therapy in Asian patients with Parkinson's disease: a narrative review and expert opinion.Therapeutic advances in neurological disorders · 2025Review
- Long-Term Real-World Experience with Safinamide in Patients with Parkinson's Disease.Brain sciences · 2024Article
- Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings.Neural regeneration research · 2024Review
- Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson's Disease.Current neuropharmacology · 2024Review
- Management of OFF condition in Parkinson disease.The mental health clinician · 2023Article
- Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Impact of Safinamide on Patient-Reported Outcomes in Parkinson's Disease.Patient related outcome measures · 2023Review
- Advances in the Pharmacological and Non-pharmacological Management of Non-motor Symptoms in Parkinson's Disease: An Update Since 2017.Current neuropharmacology · 2023Review
- Non-motor symptoms burden in motor-fluctuating patients with Parkinson's disease may be alleviated by safinamide: the VALE-SAFI study.Journal of neural transmission (Vienna, Austria : 1996) · 2022Article
- Effects of melatonin prolonged-release on both sleep and motor symptoms in Parkinson's disease: a preliminary evidence.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson's disease: A systematic review.NPJ Parkinson's disease · 2022Article
- A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Effects of safinamide on pain in patients with fluctuating Parkinson's disease.Brain and behavior · 2021Observational
- A dual timeline of safinamide effects in Parkinson's disease: mechanistic rationale and clinical implications.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-motor symptoms (NMS) are integral to Parkinson's Disease (PD) and management remains a challenge. Safinamide is a novel molecule in relation to addressing NMS due to its multifocal mechanism of action with both dopaminergic and non-dopaminergic properties.
objectiveTo investigate the efficacy of safinamide on NMS and its burden in PD patients with motor fluctuations after 6 months of treatment.
methodsThis observational, multicenter, open-label, pilot study assessed a wide range of NMS using the following rating scales, NMSS (non-motor symptom scale), KPPS (King's PD pain scale), HADS (hospital anxiety and depression scale), PDQ-8 (Parkinson's disease quality of life questionnaire), and PDSS-2 (Parkinson's disease sleep scale), EuroQol-5D 3 level version (EQ-5D-3L), CGI-I (clinical global impression of improvement), and PGI-C (patient global impression of change). Motor examination using UPDRS part III (Unified Parkinson's disease rating scale, motor examination), UPDRS IV (complications of therapy) and Hoehn and Yahr staging were also obtained.
results27 patients were included in the analysis and were evaluated at baseline and ≥ 6 months after safinamide treatment. 26 patients had a daily maintenance dose of 100 mg and 1 patient a daily dose of 50 mg. Significant improvements in UPDRS IV, KPPS item 5 (region-specific "off" dystonia), KPPS domain 3 (items 4-6, fluctuation related pain) and KPPS total score were observed after treatment with safinamide, while maintaining stable dopaminergic medication. No statistically significant differences were found in NMSS, HADS, PDSS-2, EQ-5D-3L, and PDQ-8 after treatment.
conclusionsOur results suggest that safinamide may have a beneficial effect on pain, a key unmet need in fluctuating PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.